Abstracts tagged "Bisphosphonates"

Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Paul D Miller¹, N Pannacciulli², J Malouf³, A Singer⁴, E Czerwinski⁵, HG Bone⁶, C Wang², Rachel B. Wagman² and JP Brown⁷, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Georgetown University Medical Center, Washington, DC, ⁵Krakow Medical Center, Krakow, Poland, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷CHU de Québec Research Centre and Laval University, Québec, QC, Canada
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…
Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…
Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting
Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data
Mariana O Perez¹, Diogo S Domiciano¹, Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting
The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Jeffrey R. Curtis¹, Rui Chen², Zixu (Eric) Li², Tarun Arora², Kenneth Saag³, Nicole C. Wright⁴, Shanette Daigle², Meredith Kilgore⁵ and Elizabeth Delzell⁶, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁶Retired - University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
Abstract Number: 839 • 2017 ACR/ARHP Annual Meeting
Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study
Shanshan Sheehy¹, Christine Peloquin² and Tuhina Neogi³, ¹Clinical Epidemiology Research & Training Unit, Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Bisphosphonates remain the first-line agent prescribed medication for the prevention and treatment of osteoporosis. Apart from concern about atypical fractures, another concern about risk…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 117 • 2017 Pediatric Rheumatology Symposium
The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
Simrat Morris^1,2, Syeda Maqsood³, Christine Garapic³, Andre Prochoroff³ and Hulya Bukulmez³, ¹Rainbow Babies and Childrens Hospital, Cleveland, OH, ²University Hospitals Cleveland Medical Center, Cleveland, OH, ³MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Individuals with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy have impaired bone health and increased fracture risk due to several factors including immobility,…
Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 348 • 2016 ACR/ARHP Annual Meeting
Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center
JungHee Koh¹, Seo Hwa Kim², Haneul Kim³, Min Kyung Chung³, Ji Hyeon Ju⁴ and Sung-Hwan Park⁴, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than those without, and are therefore exposed to bisphosphonates for longer. However, the increasing…
Abstract Number: 349 • 2016 ACR/ARHP Annual Meeting
Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis
Gaku Miyamura¹, Hiroki Wakabayashi², Taro Nakagawa³, Sho Kato², Yohei Naito⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu,Mie, Japan, ²Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, ³Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, ⁵Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague lower back pain. However, there have been few reports regarding the correlation between…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 2387 • 2016 ACR/ARHP Annual Meeting
Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis
Caroline Marie Andreasen¹, Anne Grethe Jurik², Mia Glerup³, Christian Høst⁴, Birgitte Thorsted Mahler⁴, Ellen-Margrethe Hauge⁵ and Troels Herlin⁶, ¹Dept. Rheumatology, Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Pamidronate (PAM) may be effective in diminishing pain and permanent bone deformities in chronic non-bacterial osteomyelitis (CNO). Whole body magnetic resonance imaging (WB MRI)…
Abstract Number: 317 • 2015 ACR/ARHP Annual Meeting
Relation of Incident Bisphosphonate Use to Trajectory of Joint-Space Width
Tuhina Neogi¹, Na Lu², Jingbo Niu¹, Jeffrey Duryea³ and Yuqing Zhang¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Radiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Trials regarding bisphosphonate (Bisph) effects in knee osteoarthritis (OA) have been conflicting, and are unable to provide insights into long-term effects. While Bisph may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].